Melanoma.
In melanoma, conventional therapies, especially cytotoxic chemotherapies, have proven unsatisfactory. Although a variety of agents have been tested singly and in combination, recent randomized studies have demonstrated that the response rates observed in single institution phase II trials are not generalizable to multi-institution settings. Studies of cytokine therapy, especially interferon-alpha in the adjuvant situation, and interleukin-2 for advanced disease, have demonstrated some utility to these agents. However, their toxicities remain formidable, and studies refining their use are under way. The limited successes of such immunomodulatory strategies have provided a rationale for continued pursuit of immunotherapy approaches. It is likely that in the near future such active immunization protocols will continue to be actively investigated.
Haluska
F G
FG
Hematology/Oncology Fellowship Training Program, Massachusetts General Hospital, Boston 02114, USA.
Multani
P S
PS
D017024:Chemotherapy, Adjuvant; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D018664:Interleukin-12 / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008545:Melanoma / Q000628:therapy*; D009367:Neoplasm Staging
D007376:Interleukin-2; D018664:Interleukin-12; D007372:Interferons